This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Market Preview: A Reason to Rally

Shares of the drug store operator are up roughly 10% in the past year, and Credit Suisse wasn't feeling too confident ahead of the print. The firm, which has a neutral rating and $38 price target on the stock, says earnings risk "looks high" for quarter and it's expecting a below-consensus profit of 51 to 53 cents a share.

"We believe Walgreens remains one of the most controversial and mistrusted names within consumer," Credit Suisse said. "Q4 sets up to be another marquee event, given recent operational headwinds, the many moving parts to this story, and the possibility for more detailed guidance. We see risk to the Q4 consensus estimate, both from technical and operational issues, but the 2013 outlook seems to be setting up more favorably. While there is risk in the near-term and numerous long-term structural challenges, we openly admit the stock seems to set up positively over the next few quarters given negative investor sentiment and improving momentum."

Despite an anticipated "strong" contribution from demand for generics, Credit Suisse expects fourth-quarter sales to be challenging and said it thinks Walgreen is also shouldering some costs from launching its loyalty program and preparing for the return of Express Scripts (ESRX) customers.

About fiscal 2013 though, the firm was feeling more optimistic.

"We project 2013 EPS at $3.05 (from $3.00), roughly in line with consensus of $3.06," Credit Suisse said. "Earnings momentum should shift positively at Walgreens in 2013, as some ESRX customers return, the company cycles easy flu and front-end comparisons, the generic wave accelerates, and synergies/accretion from AB kick-in. While there are headwinds, such as a MHS pricing reset, loyalty card/ESRX related costs, and an overall challenging competitive/consumer environment, we still see solid growth in earnings."

A slight majority of the sell side is still in wait-and-see mode on Walgreen with 16 of the 26 analysts covering the stock at hold (13), underperform (2) and sell (1). The median 12-month price target on the shares is $39 vs. Thursday's closing price of $36.60.

Check out TheStreet's quote page for Walgreen for year-to-date share performance, analyst ratings, earnings estimates and much more.

The economic calendar includes personal income and spending data for August at 8:30 a.m. ET; the Chicago purchasing managers index for September at 9:45 a.m. ET; and the final reading of the University of Michigan consumer sentiment index at 9:55 a.m. ET.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs